Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation
Audrey Le Floc’h, Jeanne Allinne, Kirsten Nagashima, et al.
Allergy (2019) Vol. 75, Iss. 5, pp. 1188-1204
Open Access | Times Cited: 328

Showing 26-50 of 328 citing articles:

Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps
Claire Hopkins, Martin Wagenmann, Claus Bachert, et al.
International Forum of Allergy & Rhinology (2021) Vol. 11, Iss. 7, pp. 1087-1101
Open Access | Times Cited: 62
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management
Marco Caminati, Bianca Olivieri, Annarita Dama, et al.
Expert Review of Respiratory Medicine (2022) Vol. 16, Iss. 7, pp. 713-721
Closed Access | Times Cited: 60
Dysregulation of the epithelial barrier by environmental and other exogenous factors
Yasutaka Mitamura, İsmail Öğülür, Yağız Pat, et al.
Contact Dermatitis (2021) Vol. 85, Iss. 6, pp. 615-626
Open Access | Times Cited: 56
Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma
Ian Pavord, Yamo Deniz, Jonathan Corren, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 11, Iss. 4, pp. 1213-1220.e2
Open Access | Times Cited: 54
IL-4/IL-13 axis as therapeutic targets in allergic rhinitis and asthma
Siti Muhamad Nur Husna, Norasnieda Md Shukri, Noor Suryani Mohd Ashari, et al.
PeerJ (2022) Vol. 10, pp. e13444-e13444
Open Access | Times Cited: 52
IgG memory B cells expressing IL4R and FCER2 are associated with atopic diseases
Carlos J. Aranda, Edgar Gonzalez‐Kozlova, Sean P. Saunders, et al.
Allergy (2022) Vol. 78, Iss. 3, pp. 752-766
Open Access | Times Cited: 47
IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline
George Scott, Seblewongel Asrat, Jeanne Allinne, et al.
Cytokine (2022) Vol. 162, pp. 156091-156091
Open Access | Times Cited: 46
Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis
El‐Bdaoui Haddad, Sonya Cyr, Kazuhiko Arima, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 7, pp. 1501-1533
Open Access | Times Cited: 45
Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies
Stella E. Lee, Claire Hopkins, Joaquim Mullol, et al.
Allergy (2022) Vol. 77, Iss. 7, pp. 2211-2221
Open Access | Times Cited: 41
Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis
Lotte S. Spekhorst, Daphne S. Bakker, Julia Drylewicz, et al.
Allergy (2022) Vol. 77, Iss. 11, pp. 3398-3407
Open Access | Times Cited: 40
Alopecia Areata: Current Treatments and New Directions
Dante Dahabreh, Seungyeon Jung, Yael Renert‐Yuval, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 6, pp. 895-912
Closed Access | Times Cited: 35
Neuroimmune interplay during type 2 inflammation: Symptoms, mechanisms, and therapeutic targets in atopic diseases
Brian Kim, Marc E. Rothenberg, Xin Sun, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 153, Iss. 4, pp. 879-893
Open Access | Times Cited: 35
New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis
Ilja Střı́ž, Korneliusz Golebski, Zuzana Střížová, et al.
Clinical Science (2023) Vol. 137, Iss. 9, pp. 727-753
Open Access | Times Cited: 33
The evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective
Eden David, Benjamin Ungar, Yael Renert‐Yuval, et al.
Clinical & Experimental Allergy (2023) Vol. 53, Iss. 2, pp. 156-172
Closed Access | Times Cited: 29
Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study
B. Molina, Roberto Padoan, Maria Letizia Urban, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 12, pp. 1587-1593
Closed Access | Times Cited: 28
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study
Leonard B. Bacharier, Jorge Máspero, Constance H. Katelaris, et al.
The Lancet Respiratory Medicine (2023) Vol. 12, Iss. 1, pp. 45-54
Closed Access | Times Cited: 28
The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis
Maddalena Napolitano, Francesca di Vico, Angelo Ruggiero, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 26
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma
Leonard B. Bacharier, Ian Pavord, Jorge Máspero, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 1, pp. 101-110
Closed Access | Times Cited: 15
Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study
Amy S. Paller, Elaine C. Siegfried, Eric L. Simpson, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 4, pp. 655-668
Open Access | Times Cited: 13
Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy
Matthew F. Wipperman, Kaitlyn Gayvert, Amanda Atanasio, et al.
Allergy (2024) Vol. 79, Iss. 4, pp. 894-907
Open Access | Times Cited: 12
Clinical Remission in Patients Affected by Severe Eosinophilic Asthma on Dupilumab Therapy: A Long-Term Real-Life Study
Carla Maria Irene Quarato, Pasquale Tondo, Donato Lacedonia, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 1, pp. 291-291
Open Access | Times Cited: 11
Dupilumab: Mechanism of action, clinical, and translational science
Marc R. McCann, Matthew P. Kosloski, Christine Xu, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 8
Open Access | Times Cited: 10
Small airways in asthma: From inflammation and pathophysiology to treatment response
Anastasia Siora, Angelos Vontetsianos, Nikolaos Chynkiamis, et al.
Respiratory Medicine (2024) Vol. 222, pp. 107532-107532
Closed Access | Times Cited: 9
Neuroinflammatory Loop in Schizophrenia, Is There a Relationship with Symptoms or Cognition Decline?
Claudio Carril Pardo, Karina Oyarce, América Vera-Montecinos
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 1, pp. 310-310
Open Access | Times Cited: 1
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
Surya P. Bhatt, Klaus F. Rabe, Nicola A. Hanania, et al.
The Lancet Respiratory Medicine (2025)
Closed Access | Times Cited: 1

Scroll to top